.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE05_Amprenavir.Amprenavir

Information

Amprenavir is a protease inhibitor antiretroviral drug used for the treatment of HIV infection. It was approved for use in combination with other antiretroviral agents for the management of HIV-1 infection in adults and pediatric patients. However, amprenavir has been discontinued in many countries and replaced by more potent protease inhibitors with better pharmacokinetic profiles.

Pharmacokinetics

Pharmacokinetic parameters observed in healthy adult volunteers (both sexes) after single oral dose administration.

References

1. Sadler, BM, et al., & Stein, DS (2001). Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects. Journal of clinical pharmacology 41(4) 386–396. DOI:10.1177/00912700122010249 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11304895

2. Barbour, AM, et al., & Wire, MB (2014). Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients. Journal of clinical pharmacology 54(2) 206–214. DOI:10.1002/jcph.205 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25272370

3. Pal, D, & Mitra, AK (2006). MDR- and CYP3A4-mediated drug-herbal interactions. Life sciences 78(18) 2131–2145. DOI:10.1016/j.lfs.2005.12.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16442130

Revisions

• 06/2025 initial generated model